Interleukin-17A and interleukin-22 production by conventional and non-conventional lymphocytes in three different end-stage lung diseases.
Melanie AlbrechtOlga HalleSvenja GaedckeSophia T PallenbergJulia Camargo NeumannMarius WittJohanna RoedigerMarina SchumacherAdan Chari JirmoGregor WarneckeDanny JonigkPeter BraubachDavid DeLucaGesine HansenAnna-Maria DittrichPublished in: Clinical & translational immunology (2022)
Our results show that both adaptive and innate lymphocyte populations contribute to IL-17A-dependent pathologies in different end-stage lung disease entities, where they establish an IL-17A-rich microenvironment. Microbial colonisation patterns and cytokine secretion upon microbial re-stimulation suggest that pathogens drive IL-17A secretion patterns in end-stage lung disease.